Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FHTX NASDAQ:HYPD NASDAQ:VYGR NASDAQ:WHWK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFHTXFoghorn Therapeutics$3.73-0.3%$4.54$3.27▼$6.95$219M2.89162,936 shs118,964 shsHYPDHyperion DeFi$2.99-14.6%$3.65$2.11▼$17.18$45.32M2.47553,742 shs800,254 shsVYGRVoyager Therapeutics$3.33-8.0%$3.88$2.83▼$5.55$201.20M1.25567,727 shs650,585 shsWHWKWhitehawk Therapeutics$4.15-5.7%$4.07$1.57▼$5.49$205.23M0.77509,020 shs124,511 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFHTXFoghorn Therapeutics-0.27%-12.85%-20.30%-35.47%-11.19%HYPDHyperion DeFi-14.57%-14.57%-17.86%-3.86%+43.75%VYGRVoyager Therapeutics-8.01%-13.95%-20.14%-14.62%+0.30%WHWKWhitehawk Therapeutics-5.68%-12.08%0.00%+10.67%+414,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFHTXFoghorn Therapeutics$3.73-0.3%$4.54$3.27▼$6.95$219M2.89162,936 shs118,964 shsHYPDHyperion DeFi$2.99-14.6%$3.65$2.11▼$17.18$45.32M2.47553,742 shs800,254 shsVYGRVoyager Therapeutics$3.33-8.0%$3.88$2.83▼$5.55$201.20M1.25567,727 shs650,585 shsWHWKWhitehawk Therapeutics$4.15-5.7%$4.07$1.57▼$5.49$205.23M0.77509,020 shs124,511 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFHTXFoghorn Therapeutics-0.27%-12.85%-20.30%-35.47%-11.19%HYPDHyperion DeFi-14.57%-14.57%-17.86%-3.86%+43.75%VYGRVoyager Therapeutics-8.01%-13.95%-20.14%-14.62%+0.30%WHWKWhitehawk Therapeutics-5.68%-12.08%0.00%+10.67%+414,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFHTXFoghorn Therapeutics 2.88Moderate Buy$11.43206.40% UpsideHYPDHyperion DeFi 2.25Hold$5.8896.49% UpsideVYGRVoyager Therapeutics 2.75Moderate Buy$16.50395.50% UpsideWHWKWhitehawk Therapeutics 2.50Moderate Buy$7.3376.71% UpsideCurrent Analyst Ratings BreakdownLatest HYPD, VYGR, WHWK, and FHTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026VYGRVoyager Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/20/2026HYPDHyperion DeFi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/8/2026WHWKWhitehawk Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.004/21/2026FHTXFoghorn Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026WHWKWhitehawk Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/16/2026WHWKWhitehawk Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$8.004/15/2026VYGRVoyager Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026HYPDHyperion DeFi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/30/2026HYPDHyperion DeFi Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026WHWKWhitehawk Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/25/2026VYGRVoyager Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFHTXFoghorn Therapeutics$30.91M7.08N/AN/A($1.92) per share-1.94HYPDHyperion DeFi$810K55.96N/AN/A$4.73 per share0.63VYGRVoyager Therapeutics$40.37M4.98N/AN/A$3.53 per share0.94WHWKWhitehawk TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFHTXFoghorn Therapeutics-$74.28M-$1.16N/AN/AN/A-266.88%N/A-35.38%8/4/2026 (Estimated)HYPDHyperion DeFi-$45.31M-$9.95N/A2.93N/AN/A-91.59%-73.08%N/AVYGRVoyager Therapeutics-$119.72M-$1.97N/AN/AN/A-319.61%-55.97%-43.12%8/5/2026 (Estimated)WHWKWhitehawk Therapeutics-$20.60M-$1.68N/AN/AN/AN/A-79.63%-74.01%N/ALatest HYPD, VYGR, WHWK, and FHTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026FHTXFoghorn Therapeutics-$0.28-$0.29-$0.01-$0.29$7.94 million$3.27 million5/7/2026Q1 2026VYGRVoyager Therapeutics-$0.54-$0.47+$0.07-$0.47$8.79 million$1.19 million5/7/2026Q1 2026WHWKWhitehawk Therapeutics-$0.36-$0.32+$0.04-$0.32N/AN/A3/26/2026Q4 2025HYPDHyperion DeFiN/A-$7.76N/A-$7.76N/A$0.50 million3/12/2026Q4 2025WHWKWhitehawk Therapeutics-$0.55-$0.34+$0.21-$0.34N/AN/A3/11/2026Q4 2025FHTXFoghorn Therapeutics-$0.30-$0.34-$0.04-$0.34$9.50 million$9.25 million3/9/2026Q4 2025VYGRVoyager Therapeutics-$0.54-$0.46+$0.08-$0.46$10.49 million$13.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/AWHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFHTXFoghorn TherapeuticsN/A2.922.92HYPDHyperion DeFi0.121.971.97VYGRVoyager TherapeuticsN/A8.428.42WHWKWhitehawk TherapeuticsN/A11.3611.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFHTXFoghorn Therapeutics61.55%HYPDHyperion DeFi25.84%VYGRVoyager Therapeutics48.03%WHWKWhitehawk Therapeutics52.08%Insider OwnershipCompanyInsider OwnershipFHTXFoghorn Therapeutics7.58%HYPDHyperion DeFi7.50%VYGRVoyager Therapeutics12.70%WHWKWhitehawk Therapeutics49.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFHTXFoghorn Therapeutics12058.71 million54.26 millionOptionableHYPDHyperion DeFi4015.16 million14.02 millionNo DataVYGRVoyager Therapeutics10060.42 million52.75 millionOptionableWHWKWhitehawk Therapeutics2149.45 million24.78 millionN/AHYPD, VYGR, WHWK, and FHTX HeadlinesRecent News About These CompaniesWhitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 5 at 2:17 AM | americanbankingnews.comWhitehawk Therapeutics (NASDAQ:WHWK) Stock Price Down 4.9% - Here's What HappenedJune 2, 2026 | americanbankingnews.comWhitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026May 30, 2026 | gurufocus.comWhitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026May 30, 2026 | prnewswire.comWhitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare ConferenceMay 28, 2026 | prnewswire.comWHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital RaiseMay 21, 2026 | finance.yahoo.comWhitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-PayloadMay 21, 2026 | prnewswire.comWhitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation SummitMay 20, 2026 | prnewswire.comWhitehawk Therapeutics officer Ball sells $201k in stockMay 18, 2026 | investing.comWhitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology ForumMay 15, 2026 | prnewswire.comWhitehawk’s First-in-Human PTK7 ADC Trial Moves Ahead: What Investors Should KnowMay 14, 2026 | theglobeandmail.comWhitehawk Therapeutics secures $87.5M PIPE financingMay 14, 2026 | seekingalpha.comWhitehawk Therapeutics Announces $87.5M Private Placement Equity FinancingMay 13, 2026 | prnewswire.comWhitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Average Rating of "Moderate Buy" from BrokeragesMay 11, 2026 | marketbeat.comWhitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsMay 7, 2026 | finanznachrichten.deWhitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsMay 7, 2026 | prnewswire.comWhitehawk Therapeutics (WHWK) price target increased by 10.29% to 6.38April 28, 2026 | msn.comWhitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026April 19, 2026 | prnewswire.comInsider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) CFO Sells 77,000 Shares of StockApril 18, 2026 | insidertrades.comWhitehawk Therapeutics, Inc. Common Stock (WHWK) Institutional HoldingsApril 17, 2026 | nasdaq.comCitizens Initiates Coverage of Whitehawk Therapeutics (WHWK) with Market Outperform RecommendationApril 17, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHYPD, VYGR, WHWK, and FHTX Company DescriptionsFoghorn Therapeutics NASDAQ:FHTX$3.73 -0.01 (-0.27%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.72 0.00 (-0.13%) As of 06/5/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Hyperion DeFi NASDAQ:HYPD$2.99 -0.51 (-14.57%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.10 +0.11 (+3.68%) As of 06/5/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Voyager Therapeutics NASDAQ:VYGR$3.33 -0.29 (-8.01%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.51 +0.18 (+5.41%) As of 06/5/2026 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.Whitehawk Therapeutics NASDAQ:WHWK$4.15 -0.25 (-5.68%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.39 +0.24 (+5.88%) As of 06/5/2026 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
